NCT05595642

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease

• Status: Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,290 (estimated)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 40 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the efficacy and safety of astegolimab compared with placebo in participants with chronic obstructive pulmonary disease (COPD) who are former or current smokers and have a history of frequent exacerbations.

Conditions

• Chronic Obstructive Pulmonary Disease (COPD)

Interventions

Type	Name	Description
DRUG	Astegolimab	Participants will receive SC astegolimab Q2W or Q4W
DRUG	Placebo	Participants will receive SC placebo Q2W

Timeline

• Start date: 2022-12-29
• Primary completion: 2025-06-24
• Completion: 2027-09-24
• First posted: 2022-10-27
• Last updated: 2026-04-02

Locations

462 sites across 38 countries: United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, France, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Kenya, Latvia, Netherlands, New Zealand, Philippines, Poland, Puerto Rico, Romania, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey (Türkiye), United Kingdom

Regulatory

• FDA-regulated drug study